AR045766A1 - Procedimiento mejorado de tratamiento de trastornos del crecimiento - Google Patents

Procedimiento mejorado de tratamiento de trastornos del crecimiento

Info

Publication number
AR045766A1
AR045766A1 ARP040103364A ARP040103364A AR045766A1 AR 045766 A1 AR045766 A1 AR 045766A1 AR P040103364 A ARP040103364 A AR P040103364A AR P040103364 A ARP040103364 A AR P040103364A AR 045766 A1 AR045766 A1 AR 045766A1
Authority
AR
Argentina
Prior art keywords
treatment
growth hormone
growth
treating
ffa
Prior art date
Application number
ARP040103364A
Other languages
English (en)
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of AR045766A1 publication Critical patent/AR045766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Tratamiento de estados patológicos y enfermedades para los cuales la hormona del crecimiento es un procedimiento deseable de tratamiento, usando reguladores de ácidos grasos libres (FFA) combinados con hormona del crecimiento. Procedimiento mejorado de tratamiento de trastornos del crecimiento, así como procedimientos para prevenir y/o reducir las consecuencias adversas del tratamiento con hormona del crecimiento. Reivindicación 14: Uso de una combinación de hormona del crecimiento y al menos un regulador de FFA en la preparación de un medicamento o composición para tratar trastornos del crecimiento en un joven. Reivindicación 26: Una composición o medicamento para tratar trastornos del crecimiento y/o prevenir o tratar las consecuencias adversas del tratamiento con hormona del crecimiento, que comprende hormona del crecimiento y al menos un regulador de FFA.
ARP040103364A 2003-09-19 2004-09-17 Procedimiento mejorado de tratamiento de trastornos del crecimiento AR045766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ52838803 2003-09-19

Publications (1)

Publication Number Publication Date
AR045766A1 true AR045766A1 (es) 2005-11-09

Family

ID=34374472

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103364A AR045766A1 (es) 2003-09-19 2004-09-17 Procedimiento mejorado de tratamiento de trastornos del crecimiento

Country Status (8)

Country Link
US (1) US20070037861A1 (es)
EP (1) EP1667671A1 (es)
JP (1) JP2007505892A (es)
AR (1) AR045766A1 (es)
BR (1) BRPI0414175A (es)
CA (1) CA2538846A1 (es)
TW (1) TW200512003A (es)
WO (1) WO2005027894A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2059260E (pt) * 2006-08-31 2013-09-03 Novartis Ag Composições farmacêuticas compreendendo hgh para distribuição oral
US9168289B2 (en) * 2011-02-01 2015-10-27 Mor Research Applications Ltd. Method of treatment of small for gestational age infants under two years of age
EP2988617B1 (en) 2013-03-27 2023-08-30 Nutritional Growth Solutions LTD Nutritional supplement for growth enhancement
PL3939590T3 (pl) * 2015-09-21 2024-03-25 Lumos Pharma, Inc. Wykrywanie i leczenie niedoboru hormonu wzrostu
US20210392934A1 (en) 2016-03-10 2021-12-23 Enzymotec Ltd. Lipid compositions and uses thereof
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue

Also Published As

Publication number Publication date
WO2005027894A1 (en) 2005-03-31
CA2538846A1 (en) 2005-03-31
EP1667671A1 (en) 2006-06-14
US20070037861A1 (en) 2007-02-15
BRPI0414175A (pt) 2006-10-31
JP2007505892A (ja) 2007-03-15
TW200512003A (en) 2005-04-01

Similar Documents

Publication Publication Date Title
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
MX2007012794A (es) Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
ATE537814T1 (de) Nanoliposom mit verestertem lecithin und herstellungsverfahren dafür und dieses enthaltende zusammensetzung zur prävention oder behandlung von hauterkrankungen
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
UY28660A1 (es) Antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento del glaucoma
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
AR048051A1 (es) Composiciones para obtener beneficios en la piel con el uso de intermediarios del metabolismo celular
AR045766A1 (es) Procedimiento mejorado de tratamiento de trastornos del crecimiento
JP2018530572A (ja) 発毛の刺激、抜け毛、フケおよびその感染症の制御のためのヘアオイルの組成物
BRPI0600326A (pt) composição fisiologicamente aceitável, usos cosméticos, usos e processos de tratamento cosmético
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
ZA202102412B (en) Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
CL2020000479A1 (es) Métodos para el tratamiento de enfermedades relacionadas con tnfa.
BR112015027569A2 (pt) compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
IT9086204A1 (it) Metodo per la cura dell'impotenza erettiva maschile
DE60107441D1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von dysphorie
Ferren Morphological differentiation of implanted brown and white fats
ES2212753B2 (es) Formula que frena la alopecia y favorece el nacimiento del cabello.
AR046572A1 (es) Uso de mejoradores de la transcripcion de enos en la terapia celular de enfermedades cardiacas isquemicas
CN204260819U (zh) 一种带纳米银涂层和限深标记的Halo头环固定针
ES1262408U (es) Tonico capilar natural; para regenerar el cabello y fortalecer su crecimiento

Legal Events

Date Code Title Description
FB Suspension of granting procedure